Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verducatib in COPD (AIRWARD)
NCT07907991Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2027
- Primary completion
- Dec 2029
01
Overview
A Phase 3 trial of verducatib in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
verducatib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07907991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907991.